FDA to discuss Merck's sugammadex

FDA's Anesthetic and Analgesic Drug Products Advisory Committee will meet on July 18 to discuss a resubmitted NDA from Merck & Co. Inc. (NYSE:MRK) for sugammadex for the reversal of neuromuscular bloc...